Pharmacological targeting of CSF1R inhibits microglial proliferation and prevents the progression of Alzheimer’s-like pathology
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The proliferation and activation of microglial cells is a hallmark of several neurodegenerative conditions. This mechanism is regulated by the activation of the colony-stimulating factor 1 receptor (CSF1R), thus providing a target that may prevent the progression of conditions such as Alzheimer’s disease. However, the study of microglial proliferation in Alzheimer’s disease and validation of the efficacy of CSF1R-inhibiting strategies have not yet been reported. In this study we found increased proliferation of microglial cells in human Alzheimer’s disease, in line with an increased upregulation of the CSF1R-dependent pro-mitogenic cascade, correlating with disease severity. Using a transgenic model of Alzheimer’s-like pathology (APPswe, PSEN1dE9; APP/PS1 mice) we define a CSF1R-dependent progressive increase in microglial proliferation, in the proximity of amyloid-β plaques. Prolonged inhibition of CSF1R in APP/PS1 mice by an orally available tyrosine kinase inhibitor (GW2580) resulted in the blockade of microglial proliferation and the shifting of the microglial inflammatory profile to an anti-inflammatory phenotype. Pharmacological targeting of CSF1R in APP/PS1 mice resulted in an improved performance in memory and behavioural tasks and a prevention of synaptic degeneration, although these changes were not correlated with a change in the number of amyloid-β plaques. Our results provide the first proof of the efficacy of CSF1R inhibition in models of Alzheimer’s disease, and validate the application of a therapeutic strategy aimed at modifying CSF1R activation as a promising approach to tackle microglial activation and the progression of Alzheimer’s disease. Microglial proliferation and activation is a hallmark of Alzheimer’s disease. Olmos-Alonso et al. show that microglial proliferation in Alzheimer’s disease tissue correlates with overactivation of the colony-stimulating factor 1 receptor (CSF1R) pathway. CSF1R blockade arrests microglial proliferation and activation in a mouse model of Alzheimer-like pathology and slows disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The absence of microglia did not significantly alter the levels of Aβ38, Aβ40, or Aβ42, in detergent-soluble or -insoluble cortical and thalamic homogenates in either the 4- or 7- month cohorts (Fig. 5a–h), in line with multiple studies showing that CSF1R inhibition does not affect Aβ production/clearance10,27,28.”
From Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Targeting CSF-1R has recently been reported to ameliorate AD pathology in APP/PS1 mice, where inhibition of CSF-1R reduced microglial proliferation and decreased the inflammatory phenotype of microglia around amyloid plaques [35].”
From Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy (2020) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Microglial proliferation has been shown to be the main contributor to increased microglial numbers under certain disease states such as ischemia, facial nerve transection, prion disease, and Alzheimer’s disease [42, 61–64].”
From IL-1β-driven amyloid plaque clearance is associated with an expansion of transcriptionally reprogrammed microglia (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While the use of these agents is limited in experimental TBI studies, several groups have reported that microglial elimination [via colony-stimulating factor 1 receptor (CSF1R) inhibition] improves behavioral performance and synaptic functioning independent of Aβ accumulation in multiple transgenic mouse models of AD (3xTg, 5xFAD, APP/PS1) (236–238).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [237]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“activated microglia in AD show increased proliferation (63,64) and increased expression of inflammatory markers such as CD36, CD14, CD11c, MHC-II, and iNOS (65,66)”
From Microglia in Alzheimer's disease (2017) · cites this paper as [64]
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 5×
“…pathogenesis is supported by recent genome-wide association studies, highlighting immune-related genes such as CR1 (Jun et al., 2010), TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013) or HLA-DRB5–HLA-DRB1 in association with Alzheimer’s disease (European Alzheimer’s Disease et al.,…”
ResultInfluentialVariant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 5×
“The contribution of inflammation to disease pathogenesis is supported by recent genome-wide association studies, highlighting immune-related genes such as CR1 (Jun et al., 2010), TREM2 (Guerreiro et al., 2013; Jonsson et al., 2013) or HLA-DRB5–HLA-DRB1 in association with Alzheimer’s disease (European Alzheimer’s Dise…”
InfluentialCSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463 · cited 2×
“The therapeutic potential of CSF1R inhibitors has been suggested in inflammatory diseases, autoimmune dis- orders, bone disease and cancer (Burns and Wilks, 2011; Pyonteck et al., 2013).”
BackgroundMethodNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 4×
“, 2009), together with tangle pathology (Nelson et al., 2012) or neurodegeneration-related biomarkers (Wirth et al.”
BackgroundInfluentialElmore, M. R. P., Najafi, A. R., Koike, M. A., Dagher, N. N., Spangenberg, E. E., Rice, R. A., Kitazawa, M., Matusow, B., Nguyen, H., West, B. L., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.02.040 · Cited by 1,968
Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease
Zhang, B., Gaiteri, C., Bodea, L.-G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., Zhang, C., Xie, T., Tran, L., Dobrin, R., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.030 · Cited by 1,657 · cited 1×
“Activated microglia have been demonstrated in transgenic models of Alzheimer’s disease (LaFerla and Oddo, 2005; Jucker, 2010) and have been recently shown to dominate the gene expression landscape of patients with Alzheimer’s disease (Zhang et al., 2013).”
BackgroundMicroglia in neurodegenerative disease
Perry, V. H., Nicoll, J. A. R., & Holmes, C. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.17 · Cited by 1,543 · cited 2×
“microglia with an activated phenotype (Perry et al., 2010)”
BackgroundSelf-citation
Cited by
Items 501–533 of 533
Inflammatory Mediators Both Directly and Indirectly Promote Microglial Proliferation
Hammond, B. P., Hahn, E., Lee, K. V., Kerr, B. J., & Plemel, J. R. (2026) · Glia · doi:10.1002/glia.70150
Kim, D., Kondo, T., Imamura, K., Tsukita, K., Nagahashi, A., Sakasai, T., & Inoue, H. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71074 · Cited by 1
Jiang, N. (2019) · theses.fr (ABES) · doi:10.70675/e788b268zc8e3z491az8d02z52080880e988 · Cited by 1
Bringuier, C. M. (2020) · theses.fr (ABES) · doi:10.70675/e40cbaaazaec8z46aazaf4fz41b8415fd687
Staging concept for aging management: Definition, mechanism, and coping strategies
Wang, Z., Liu, S. S., Du, S., Cui, X., Chao, B., Liu, M., & Wu, M. (2026) · View · doi:10.1002/viw.20250201
Mechanisms controlling microglial colonization of the forebrain
Bridlance, C. (2023) · theses.fr (ABES) · doi:10.70675/5879aa36z8649z48f9zb359zf349ce3cb429
Pathophysiology and Molecular Mechanisms of Alzheimer’s Disease
Chandragiri, S. S., Mathur, M., & Mathur, N. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814953126010005
Lee, H.-J., Seok, J., Kang, S., Oh, S., Hwang, J.-W., Kim, Y., Seo, J., & Hoe, H. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03855-7
Wijesinha, D. (2026) · Sri Lanka Journal of Neurology · doi:10.4038/sljon.v12i2.211
Microglial activation and neuroinflammation: implications for neuropsychiatric symptoms
Uddin, T., Halder, C., Asma, A., Zaheen, A., Nahian, A., Nipun, R. S., Ferdous, J., Sarker, R., Misha, M., Tasnim, S., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004158
Chronic pain in Alzheimer disease and the role of neuroimmune interactions
Malcangio, M., & Sideris-Lampretsas, G. (2026) · Pharmacological Reviews · doi:10.1016/j.pharmr.2026.100149
Cao, P., Yu, J., Duan, N., Li, Y., & Cui, J. (2026) · Neurochemical Journal · doi:10.1134/s1819712426700340
Single-cell discovery of mTOR-associated microglial clusters in human mTORopathies
Kalf, R. S., Scheper, M., Horst, E. F., Anink, J. J., Jansen, F. E., Hecke, W. V., Mühlebner, A., van Vliet, E. A., Mills, J. D., & Aronica, E. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02467-9
Targeting Microglial Receptors for Alzheimer’s Disease: Translational Barriers from Bench to Bedside
Tang, X., Hasan, I., & Xu, J. (2026) · Neuropharmacology and Therapy · doi:10.15212/npt-2026-0008
Wu, Y., Duan, L., Zhang, L., Wang, S., Yan, H., He, M., Wang, T., Li, L., & Gao, Y. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1912989 · Cited by 1
Xu, L., Zhang, Y., Jiang, L., Xing, J. F., Hu, J., Lan, T., & Ta, G. (2026) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2026.1902577
Stelmack, H. D. R. L. (2026) · Revista Científica Ipedss · doi:10.55703/27644006060306
Ledesma‐Corvi, S., Blankers, S. A., McGovern, A. J., Towriss, M., Kim, J. S., Ciernia, A. V., & Galea, L. A. M. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.31.748388
Hossain, M. M., Singdha, T. R., Sakib, S. I., Adhikari, J., Choudhury, P., Miya, M. S., Sarker, A. K., Das, M., & Shibly, A. Z. (2026) · Bioinformatics and Biology Insights · doi:10.1177/11779322261489770
Morató, X., Marquié, M., Tartari, J., Lafuente, A., Sáez, M., Montoliu-Gaya, L., Huber, H., Alegret, M., Jofresa, S., Buendía, M., et al. (2026) · Journal of Alzheimer's Disease · doi:10.1177/13872877261490130
[3H]5-MOP: a novel and selective colony stimulating factor-1 receptor (CSF1R) radiotracer
Iavazzo, C., Pazarlar, B. A., Bang‐Andersen, B., Jensen, T. N., Hentzer, M., Bastlund, J. F., Haslund-Vinding, J. L., Mathiesen, T. I., Lambertsen, K. L., Finsen, B. R., et al. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01520-x
BindingDB (2023) · UC San Diego · doi:10.7270/q29w0kgp
BindingDB (2025) · UC San Diego · doi:10.7270/q2p273sq
BindingDB Entry 50019715: Synthesis and Development of Highly Selective Pyrrolo[2,3-
BindingDB (2024) · UC San Diego · doi:10.7270/q2w66r6t
BindingDB Entry 50022423: The latest perspectives of small molecules FMS kinase inhibitors.
BindingDB (2025) · UC San Diego · doi:10.7270/q2057mnz
Metadata
- Authors
- Olmos-Alonso, A., Schetters, S. T. T., Sri, S., Askew, K., Mancuso, R., Vargas-Caballero, M., Holscher, C., Perry, V. H., & Gomez-Nicola, D.
- Affiliations
- University of Southampton (GB)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-01-08
- Volume
- 139
- Issue
- 3
- Pages
- 891-907
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4766375
- OpenAlex
- W2222356562
- Cited by
- 532
- References
- 66
- Citations by year
- 2026: 38 · 2025: 50 · 2024: 50 · 2023: 57 · 2022: 45 · 2021: 79 · 2020: 51 · 2019: 44 · 2018: 51 · 2017: 37 · 2016: 30
- FWCI
- 29.59
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Brain (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Lancaster EPrints (Lancaster University) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Alzheimer's Society
- Medical Research Council (MR/K022687/1)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- CSF1R inhibition, microglial proliferation, Alzheimer's disease, GW2580, tyrosine kinase inhibitors, APP/PS1 mice, amyloid plaques, microglial activation, anti-inflammatory phenotype, synaptic degeneration, memory impairment, neuroinflammation, disease progression
- MeSH terms
- Alzheimer Disease, Animals, Anisoles, Female, Humans, Male, Mice, Inbred C57BL, Mice, Transgenic, Pyrimidines, Receptors, Granulocyte-Macrophage Colony-Stimulating Factor, Drug Delivery Systems, Microglia, Disease Progression, Protein Kinase Inhibitors, Cell Proliferation, Mice, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.